To determine if there are markers of disease such as proteins or genes (biomarkers) in blood, lung tissue or other body fluids that can be used to predict the course of IPF.
135 subjects will be recruited with a goal of following approximately 100 subjects in the longitudinal follow up phase.
- Approximately 9 visits over 80 weeks
- Screening visit to determine eligibility
- Study visits every 16 weeks up to a maximum of 80 weeks